Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Q&A: Mario Romano discusses temperature during vitrectomy | Ophthalmology Times
Photo of Mario Romano at EURETINA 2025 Mario Romano, MD, PhD, a researcher from Humanitas University in Italy, discusses work on temperature control during vitrectomy. His research, supported by the Italian Ministry of Research, reveals significant temperature drops during eye…
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Q&A: Nadia Waheed on the role of OCT in the future of ophthalmology | Ophthalmology Times
Photo of Nadia Waheed at the 2025 EURETINA meeting held in Paris, France Ultra High Resolution OCT is revolutionizing retinal imaging, offering unprecedented insights into eye diseases. Nadia Waheed, MD, MPH, from Tufts University School of Medicine discusses how this…
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial | Ophthalmology Times
Photo of Patricio Schlottmann at the 2025 EURETINA meeting in Paris, France Patricio Schlottmann, MD, a retina specialist from Buenos Aires, Argentina, discusses the AVONELLE-X extension study of faricimab, a treatment for wet age-related macular degeneration (AMD). The study, spanning…
Q&A: Alexandra Miere discusses the ACTOR and HERMES studies | Ophthalmology Times
Photo of Alexandra Miere at the 2025 EURETINA meeting in Paris Alexandra Miere discusses retinal studies published in EURETINA journal. The first, the ACTOR study, explores vascular remodeling in neovascular AMD patients treated with ranibizumab. The second, the HERMES study,…
Researchers assess atropine and cyclopentolate for detecting premyopia in young children | Ophthalmology Times
(Image Credit: AdobeStock) A comparison of 2 cycloplegic agents, atropine and cyclopentolate, in preschool children for cycloplegia found that atropine was associated with less myopic refraction compared with cyclopentolate and may potentially avoid the overestimation of premyopia prevalence,1 reported first…
Anniversary of the spectral OCT prototype: 25 years young and growing | Ophthalmology Times
A recent conference celebrated the creation of the first prototype of the spectral optical coherence tomography (SOCT) instrument. Introduced in 2000, the prototype, which was developed at the Institute of Physics of Nicolaus Copernicus University in Toruń, Poland, was the…
Kala Bio’s CHASE trial misses primary endpoint, KPI-012 development discontinued | Ophthalmology Times
(Image Credit: AdobeStock) Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect (PCED), did not meet its primary endpoint. Additionally, the company noted that the trial failed to show statistical significance…
The Netherlands: Lupin strengthens ophthalmology business with acquisition of VISUfarma from GHO Capital
\n European specialist investor GHO Capital Partners has announced the sale of its portfolio company, VISUfarma, a Netherlands-headquartered specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin. \n\n\n\n VISUfarma was created by GHO Capital in 2016 by combining…
Q&A: Harvey Uy on the power of digital images and records | Ophthalmology Times
Photo of Harvey Uy, MD, DPBO, FVRSP, at the 2025 EURETINA meeting Harvey Uy, MD, DPBO, FVRDP, a retina specialist from the Peregrine Eye and Laser Institute in the Philippines, discussed the transformative power of digital image management in ophthalmology.…